Payment overview · 2025
General Payments
$2,981.09
149 reported records · 30 companies
Healthcare provider profile · identity verified
George Anastasio
Allopathic & Osteopathic Physicians|Family Medicine · SUFFIELD, CT · NPI 1770508087
Verified facts
What the public records show
CMS Open Payments records show George Anastasio received $2,981.09 in general payments during 2025 across 149 reported records.
ABBVIE INC. accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Entresto, Jardiance, Mounjaro, Ozempic, Paxlovid, Prolia, Rybelsus, Synthroid, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Soliqua 100-33 by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $425.55 | 14.3% | 31 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $410.49 | 13.8% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.79 | 6.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $184.58 | 6.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $130.63 | 4.4% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $128.63 | 4.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $119.41 | 4.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.71 | 3.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $108.36 | 3.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.61 | 3.2% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.68 | 3.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.17 | 3.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.64 | 3.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $83.82 | 2.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.35 | 2.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $80.89 | 2.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.98 | 2.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $59.86 | 2.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $56.01 | 1.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.73 | 1.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.22 | 1.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.58 | 1.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $41.29 | 1.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.96 | 1.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $34.05 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.83 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.93 | 0.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.70 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.30 | 0.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.34 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,981.09 | 149 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $230.12 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $216.44 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $190.00 | 13 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $136.49 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $136.49 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.37 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $130.63 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $128.63 | 6 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $126.95 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $109.71 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $97.56 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.59 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $95.61 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.54 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $83.82 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $81.35 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $80.89 | 3 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $77.37 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.81 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $63.98 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.88 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.31 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $60.43 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $59.86 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $56.01 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $54.39 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 322 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 251 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 33 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 23 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
297 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
322 | 73 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
322 | 73 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
251 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 754 | 215 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 492 | 157 |
| Lisinopril | Lisinopril | 451 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 351 | 97 |
| Losartan Potassium | Losartan Potassium | 346 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 89 |
| Jardiance | Empagliflozin | 322 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 316 | 96 |
| Farxiga | Dapagliflozin Propanediol | 297 | 66 |
| Simvastatin | Simvastatin | 268 | 68 |
| Metformin Hcl | Metformin Hcl | 258 | 78 |
| Ozempic | Semaglutide | 251 | 53 |
| Eliquis | Apixaban | 230 | 50 |
| Alprazolam | Alprazolam | 228 | 43 |
| Omeprazole | Omeprazole | 217 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 54 |
| Furosemide | Furosemide | 194 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 183 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 177 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 53 |
| Tramadol Hcl | Tramadol Hcl | 173 | 36 |
| Meloxicam | Meloxicam | 168 | 40 |
| Allopurinol | Allopurinol | 164 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 43 |
| Carvedilol | Carvedilol | 155 | 42 |
| Gabapentin | Gabapentin | 154 | 37 |
| Lorazepam | Lorazepam | 135 | 29 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 129 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 33 |
| Alendronate Sodium | Alendronate Sodium | 122 | 31 |
| Finasteride | Finasteride | 119 | 32 |
| Trazodone Hcl | Trazodone Hcl | 110 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 28 |
| Pregabalin | Pregabalin | 97 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 93 | 19 |
| Potassium Chloride | Potassium Chloride | 88 | 23 |
| Vascepa | Icosapent Ethyl | 88 | 13 |
| Mounjaro | Tirzepatide | 87 | 17 |
| Montelukast Sodium | Montelukast Sodium | 84 | 19 |
| Donepezil Hcl | Donepezil Hcl | 83 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 22 |
| Sertraline Hcl | Sertraline Hcl | 80 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 21 |
| Atenolol | Atenolol | 77 | 23 |
| Famotidine | Famotidine | 77 | 21 |
| Ezetimibe | Ezetimibe | 72 | 21 |
| Valsartan | Valsartan | 72 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 27 |
| Synthroid | Levothyroxine Sodium | 70 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 64 | 17 |
| Trulicity | Dulaglutide | 61 | 11 |
| Mirtazapine | Mirtazapine | 60 | 18 |
| Spironolactone | Spironolactone | 58 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Xarelto | Rivaroxaban | 57 | 15 |
| Metformin Hcl Er | Metformin Hcl | 56 | 14 |
| Novolog Flexpen | Insulin Aspart | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 12 |
| Irbesartan | Irbesartan | 53 | 15 |
| Prednisone | Prednisone | 53 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 52 | 52 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 20 |
| Azithromycin | Azithromycin | 49 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 14 |
| Clonazepam | Clonazepam | 45 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Ramipril | Ramipril | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 12 |
| Primidone | Primidone | 40 | suppressed |
| Lansoprazole | Lansoprazole | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Edarbi | Azilsartan Medoxomil | 34 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Colchicine | Colchicine | 32 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Azelastine Hcl | Azelastine Hcl | 29 | 13 |
| Myrbetriq | Mirabegron | 29 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 25 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 12 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Oxazepam | Oxazepam | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Cephalexin | Cephalexin | 23 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Prolia | Denosumab | 23 | 14 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Topiramate | Topiramate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,981.09 · 149 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, ALVESCO, AUSTEDO XR, Auvelity, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, GEMTESA, GLASSIA, HORIZANT, ID NOW INSTRUMENT, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error